For women with rare diseases, they often face a double jeopardy, where many of the symptoms they experience can be confused with and misdiagnosed as menopause. In a new pharmaphorum podcast, web ...

In Part 5 of our Life Sciences Industry Report, we turn our attention to the oncological field of research and development, from cancer therapies to cancer care, from clinical trials to the patient’s ...

Take a look at three predictions for the year ahead for pharma executives considering AI implementation and adoption. For AI to live up to its potential, pharma executives need to not simply invest in ...

Spinraza remains a big product for Biogen but has seen its sales go into reverse as competition in SMA treatment has emerged ...

BV100 is a new formulation of rifabutin suitable for intravenous administration that BioVersys claims offers a new mechanism ...

President Trump's pick to lead the Department of Health and Human Services (HHS), Robert F Kennedy Jr, will be scrutinised at ...

The innovation showcased at CES highlights how practical solutions can meet niche, but impactful, health challenges. These ...

The ranges were 4.5 to nine years for men and 6.5 to 11 years for women, according to the researchers, who have published ...

The new data comes from the phase 3 ALLEVIATE-1 trial, which compared cebranopadol to placebo for the management of ...

Pfizer has decided to discontinue the development of another of its experimental obesity therapies, after seeing high rates of discontinuation with the drug in a mid-stage trial. The company is ...

Boehringer Ingelheim has taken an option on a family of compounds with potential as therapies for schizophrenia from Sosei Heptares, which it says could have broad activity against the symptoms of ...

Eli Lilly has said it is prepared to invest £279 million ($364 million) in the UK and work with the government to tackle serious public health challenges, including obesity. The proposal ...